SRChing for the substrates of Src.

Reynolds AB, Kanner SB, Bouton AH, Schaller MD, Weed SA, Flynn DC, Parsons JT
Oncogene. 2014 33 (37): 4537-47

PMID: 24121272 · DOI:10.1038/onc.2013.416

By the mid 1980's, it was clear that the transforming activity of oncogenic Src was linked to the activity of its tyrosine kinase domain and attention turned to identifying substrates, the putative next level of control in the pathway to transformation. Among the first to recognize the potential of phosphotyrosine-specific antibodies, Parsons and colleagues launched a risky shotgun-based approach that led ultimately to the cDNA cloning and functional characterization of many of today's best-known Src substrates (for example, p85-Cortactin, p110-AFAP1, p130Cas, p125FAK and p120-catenin). Two decades and over 6000 citations later, the original goals of the project may be seen as secondary to the enormous impact of these protein substrates in many areas of biology. At the request of the editors, this review is not restricted to the current status of the substrates, but reflects also on the anatomy of the project itself and some of the challenges and decisions encountered along the way.

MeSH Terms (14)

Animals Catenins Cell Transformation, Neoplastic Cortactin Crk-Associated Substrate Protein Focal Adhesion Kinase 1 Gene Expression Regulation, Neoplastic Humans Mice Microfilament Proteins Neoplasms Phosphorylation Proteome src-Family Kinases

Connections (2)

This publication is referenced by other Labnodes entities: